| Domain | Variable | Numerator/Denominator | Frequency / Value | Notes |
|---|---|---:|---:|---|
| Cohort | Total patients included | 210/210 | 210 patients | Systematic review cohort size; median age 22 years (Sun et al., *Frontiers in Endocrinology*, Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000000) |
| Demographics | Female:male ratio | — | 2:1 | Female predominance in pooled cohort; most patients were 10–30 years old (71.88%) (Sun et al., Jun 2024, DOI above) (pqac-00000000, pqac-00000004) |
| Demographics | Age distribution 10–30 years | — | 71.88% | Majority presented in adolescence/young adulthood (Sun et al., Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000004) |
| Carney complex association | Concurrent Carney complex (CNC) | 66/210 | 31.43% | cPPNAD/CNC subset in pooled review (Sun et al., Jun 2024, DOI above) (pqac-00000000, pqac-00000004) |
| CNC phenotype | Spotty skin pigmentation among cPPNAD/CNC | 47/66 | 71.21% | Pigmentary findings common in CNC-associated cases; supports PRKAR1A testing consideration (Sun et al., Jun 2024, DOI above) (pqac-00000004, pqac-00000005) |
| CNC phenotype | Cardiac or cutaneous myxoma among cPPNAD/CNC | 19/66 | 28.79% | Relevant for surveillance due to embolic risk in CNC (Sun et al., Jun 2024, DOI above) (pqac-00000006) |
| Major phenotype | Osteoporosis / osteopenia | 33/35 | 94.29% | One of the most frequent reported morbidity features (Sun et al., Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000000, pqac-00000004) |
| Major phenotype | Hypertension | 81/120 | 67.50% | Common hypercortisolism-related comorbidity (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Major phenotype | Weight gain | 71/120 | 59.17% | Typical Cushing syndrome manifestation in pooled cases (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Diagnostic laboratory | Loss of cortisol circadian rhythm | 70/71 | 98.59% | Strong biochemical hallmark of hypercortisolism (Sun et al., Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000004) |
| Diagnostic laboratory | Low/undetectable ACTH | 77/98 | 78.57% | Consistent with ACTH-independent Cushing syndrome (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Diagnostic laboratory | Plasma cortisol not suppressed on dexamethasone testing | 31/31 | 100% | Included paradoxical or absent suppression on low-/high-dose dexamethasone/Liddle-type testing (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Genetics | Patients undergoing genetic testing | 151/210 | 71.90% | Not all published cases had molecular testing (Sun et al., Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000000, pqac-00000005) |
| Genetics | Any pathogenic variant detected | 132/151 | 87.42% | High diagnostic yield in tested cases (Sun et al., Jun 2024, DOI above) (pqac-00000000, pqac-00000004) |
| Genetics | Genes reported in cohort | — | 6 genes | PRKAR1A, PDE11A, PRKACA, CTNNB1, PDE8B, ARMC5 (Sun et al., Jun 2024, DOI above) (pqac-00000000, pqac-00000004) |
| Genetics | PRKAR1A pathogenic variants | 120/151 | 79.47% | Most common implicated gene in tested patients (Sun et al., Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000000, pqac-00000004) |
| Genetics | PDE11A variants | 40/151 | 26.49% | Some patients carried PDE11A along with PRKAR1A (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Genetics | PRKAR1A + PDE11A co-occurrence | 33/151 | 21.85% | Reported overlap among genetically tested cases (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Genotype-phenotype | Spotty pigmentation with PRKAR1A variant among evaluable CNC cases | 33/45 | 73.33% | Significant association reported between PRKAR1A and spotty skin pigmentation in CNC with PPNAD (Sun et al., Jun 2024, DOI above) (pqac-00000000, pqac-00000004) |
| Surgery | Any surgery data available | 122/210 | 58.10% | Surgical approach reported for subset of pooled cases (Sun et al., Jun 2024, https://doi.org/10.3389/fendo.2024.1356870) (pqac-00000004) |
| Surgery | Bilateral adrenalectomy | 62/122 | 50.82% | Most common surgical treatment in reported cases (Sun et al., Jun 2024, DOI above) (pqac-00000004) |
| Surgery | Unilateral adrenalectomy | 41/122 | 33.61% | Considered in selected patients; review discusses fertility/pregnancy considerations (Sun et al., Jun 2024, DOI above) (pqac-00000004, pqac-00000005) |
| Surgery | Two-stage bilateral adrenalectomy | 15/122 | 12.30% | Often reflects completion adrenalectomy after initial unilateral approach (Sun et al., Jun 2024, DOI above) (pqac-00000004) |


*Table: This table compiles the main quantitative findings from Sun et al. 2024’s systematic review of 210 PPNAD patients, including demographics, phenotype frequencies, diagnostic findings, genetic results, and surgery patterns. It is useful as a concise evidence summary for knowledge-base curation and clinical overview.*